HB1768 is an omnibus bill that bundles environmental, technology and a very large healthcare package. The healthcare sections reauthorize pandemic and public‑health programs, extend and tweak dozens of Medicare and Medicaid policies, add new reporting and anti‑abuse controls for pharmacy benefit managers (PBMs), and change enrollment, screening, and program integrity rules across federal health programs.
It also extends and funds multiple prevention, addiction, maternal‑health and public‑health initiatives.
Why it matters: the bill shifts how drug rebates and PBM revenues flow (imposing full pass‑through and new, detailed reporting), tightens program integrity controls across Medicaid/Medicare (quarterly death‑file checks, streamlined out‑of‑state provider enrollment), and locks in several telehealth and public‑health authorities through 2026–2029. For compliance officers, payers and provider finance teams this is a high‑impact package: new data submission and auditing duties, new payment and reporting deadlines, and fresh grant and procurement opportunities for public‑health preparedness.
At a Glance
What It Does
Requires PBMs and related intermediaries to remit and transparently report monies tied to drug utilization, creates binding semi‑annual reporting in machine‑readable form to plans, extends telehealth and several Medicare payment waivers, tightens Medicaid provider/beneficiary verification, reauthorizes major public‑health and preparedness funding and creates new supply‑chain, biodefense and pandemic laboratory initiatives.
Who It Affects
Health plans (including large‑employer self‑funded plans), MA and Part D sponsors, PBMs and affiliated pharmacies, hospitals (especially rural/low‑volume), Medicaid agencies and state public‑health programs, community health centers, and manufacturers/suppliers in the medical countermeasure and diagnostic supply chains.
Why It Matters
The bill changes incentives and reporting across the drug supply chain (rebates, fees, audits), adds program integrity duties that will drive vendor and contract reviews, extends pandemic and emergency authorities that affect procurement and stockpile planning, and creates multiple new funding streams for state/Tribal public‑health efforts.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
This bill is a broad package; the healthcare and public‑health components are clustered across multiple titles. It reauthorizes core preparedness and public‑health programs (epidemic intelligence, Hospital Preparedness Program, National Disaster Medical System) and adds new, longer‑term items: regional biocontainment labs, expanded wastewater surveillance grants, and a Department of Commerce‑led supply‑chain work program.
Those changes are meant to increase domestic capacity for diagnostics, countermeasures and surge response.
On the care‑delivery side the bill extends a long list of Medicare flexibilities (telehealth waivers, acute hospital care at home, certain payment add‑ons and rural hospital adjustments) and makes discrete changes in Medicare and Medicaid operations: a streamlined enrollment path for eligible out‑of‑state Medicaid providers; quarterly checks of death‑records to prevent ghost providers and improper payments; and an inventory/reporting regime for what recyclers and procurement folks will care about. The bill also reauthorizes and expands many prevention and behavioral‑health programs, and reissues funding for community health centers, maternal health research and opioid‑related programs.Arguably the most consequential insurer‑facing items are PBM and pharmacy transparency and accountability measures.
The bill requires detailed, machine‑readable reports from entities that manage prescription benefits (semiannually or more often at a plan’s request), makes (with a delayed effective date) PBMs remit 100% of drug rebates and other price concessions that relate to plan drug spending to the plan (with quarterly remittance and audit rights), and creates civil and administrative remedies and reporting obligations for non‑compliance. To support monitoring, plans and third‑party auditors will get access to contracts and rebate data—subject to privacy safeguards.
Those provisions are paired with ERISA/IRS/FTC/DoL conformity and civil‑penalty authorities so enforcement can be pursued through multiple avenues.The bill is densely operational: it sets deadlines and timeframes for FDA and HHS action, requires new guidance and rulemaking (for PBM reporting formats, telehealth modifier requirements, and clinical trial/pediatric drug study rules), and creates an expectation that plans, vendors and state agencies build systems for automated reporting, pharmacy‑level audits and enhanced procurement oversight. Implementation will therefore be an exercise in contract remediation, data engineering and regulatory engagement for plans, PBMs, vendors and providers.
The Five Things You Need to Know
The bill requires entities providing PBM services to remit 100% of rebates, fees and other price concessions related to plan drug spending to the plan (quarterly remittances; audits and disclosure required) — the rule takes effect 30 months after enactment.
PBMs, health plans and issuers must produce standard, machine‑readable semiannual reports (or quarterly at a plan’s request) detailing claims, per‑drug costs, net spending, rebates/fees collected and retained, dispensing channels and benefit design impact — the Secretary must prescribe the format within 18 months.
Medicaid changes include a streamlined enrollment pathway for eligible out‑of‑state providers (effective in 3 years) and mandatory quarterly checks of the Death Master File for enrolled providers and beneficiaries starting January 1, 2026.
A swath of Medicare and public‑health flexibilities are extended: key telehealth waivers, FQHC/RHC telehealth payment rules, acute hospital care‑at‑home authority and several Medicare low‑volume and DSH adjustments — many extensions run through Dec. 31, 2026 or longer for other programs.
The bill funds and reauthorizes preparedness and research programs (regional biocontainment labs, diagnostics/ wastewater surveillance grants, epidemic intelligence and countermeasure R&D), and adds new supply‑chain resilience tasks for Commerce to coordinate critical technology assessments.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Recycling infrastructure, reporting and grants
Three new EPA authorities expand federal data collection and facility inventories, create a Recycling Infrastructure and Accessibility competitive grant program ($30M/year FY25‑29), and require EPA to estimate national recycling rates and publish end‑market price data. Practically: manufacturers, states and MRF operators will face new reporting, and local governments can apply for hub‑and‑spoke grants targeting underserved communities.
Medicaid enrollment, integrity and access tweaks
The bill requires states to adopt a streamlined enrollment option for certain out‑of‑state providers (eligible providers) and to conduct quarterly Death Master File checks on enrolled providers; it delays certain juvenile justice‑related screen changes, directs studies on maternity care costs, and requires states to make address verification improvements. Compliance offices should note new state plan obligations, matching‑fund rules for grants, and concrete timelines for implementation.
Medicare extensions, new reporting and program tweaks
Medicare provisions extend multiple temporary payment and program flexibilities, add short‑term increases (e.g., physician fee adjustments for 2025), extend low‑volume and rural hospital supports, and keep telehealth flexibilities through 12/31/2026 (with specific rules for FQHC/RHC, hospice face‑to‑face, and audio‑only). The bill also requires expanded data collection and reporting on drugs, adds PBM‑focused transparency and contracting rules that touch Part D sponsors, and creates more auditing and enforcement pathways tied to those disclosures.
PBM transparency, rebate pass‑through and ERISA/IRS hooks
A coordinated set of statutory changes (Public Health Service Act, ERISA, Internal Revenue Code) requires PBMs to remit rebates/price concessions to plans, provide semi‑annual machine‑readable reports with claim‑ and drug‑level detail, and exposes non‑compliant plans/PBMs to civil penalties. ERISA and tax code changes align enforcement across regulatory systems. The measures are drafted to enable plan audits and to push rebate flows to plan sponsors rather than intermediate capture by PBMs; implementation will require new data feeds and contract renegotiations.
SUPPORT Act reauthorization and targeted addiction programs
The legislation reauthorizes core prevention, treatment and recovery grants — including expanded funding for evidence‑based maternal and perinatal programs, recovery housing pilots, youth prevention and recovery grants, and the National Drug Overdose Prevention program — and clarifies State/Tribal roles for some pilot programs. Grants include new language allowing distribution of fentanyl‑test supplies where lawful and emphasize workforce and peer support.
Reauthorizations, new centers and supply‑chain work
Reauthorizations extend epidemic intelligence, biodefense contracting, SNS appropriations and the BARDA and PHEMCE mission set; add regional biocontainment lab awards, wastewater surveillance grants, and supply‑chain resilience work led by Commerce. The bill also directs studies (GAO, NIH, Academies) and requires updated strategies and exercise‑driven readiness planning, all with near‑term funding to sustain preparedness capacities.
Tech policy, blockchain, telecom and venue transparency
Separate divisions cover consumer safety (sodium nitrite bans, battery standards), a new Abraham Accords FDA office to coordinate with allied regulators, NTIA and FCC taskforces on spectrum and future networks (6G), and consumer‑facing transparency requirements (hotel fees, ticketing). The tech titles also direct DoC to lead a blockchain advisory committee and fund NTIA offices.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare and employer plan sponsors — will receive more of the pharmacy channel economics (rebates and price concessions) that PBMs currently retain, improving plan budgets and enabling potential premium or benefit adjustments.
- Patients and beneficiaries — extensions of telehealth and hospice flexibilities and conservation of acute‑hospital‑at‑home programs increase care access; antidiscrimination and maternal health programs target improved outcomes for at‑risk populations.
- State and local public health programs — new grant authorities (wastewater surveillance, recycling grants, regional labs, preparedness grants) create funding and technical‑assistance opportunities to expand surveillance, surge capacity and community response.
- Rural and underserved communities — dedicated recycling infrastructure grants, hospital and DSH adjustments, and extended community health center funding increase resources where capacity is thin.
- Clinical and research communities — expanded maternal, pediatric, FASD and traumatic brain injury research and reauthorizations create predictable federal funding for cohort studies, translational projects and prevention research.
Who Bears the Cost
- Pharmacy benefit managers and some affiliated pharmacies — the bill forces full rebate pass‑through and heavier reporting, compressing PR margins and requiring new systems for quarterly remittance and disclosure.
- Plans and issuers — new reporting, auditing and contracting requirements create near‑term compliance costs, data‑engineering needs and potential legal exposure when vendor disclosures reveal gaps.
- Manufacturers, wholesalers and GPOs — new transparency requirements and tighter contract audits make commercial arrangements more visible and potentially renegotiable; some pricing strategies may be affected.
- States and small providers — many new grant application, data submission and procurement processes increase administrative workload; unfunded mandates risk for agencies without dedicated implementation funding.
- Federal agencies — HHS, FDA, EPA, NTIA, and Commerce are assigned new reporting, rulemaking and program‑management responsibilities that will require staff, systems and interagency coordination.
Key Issues
The Core Tension
The central dilemma: HB1768 tries to force money and data back to payers, boost public‑health surge capacity and expand access (telehealth, maternal research), while avoiding price shocks and maintaining private‑sector incentives for innovation. You can increase transparency and capture public value from rebates, but you risk destabilizing existing contracting models, spurring litigation and shifting costs if valuable intermediary services are priced out or if implementation is rushed. The bill solves one problem (opportunity for plans and public health) while creating hard governance and operational work that will determine whether the stated savings and access goals are realized.
The bill uses a mix of direct mandates, reporting requirements and grant authorities to change incentives across health and public‑health systems. That design pushes transparency and cash to plans and states while relying on audits and enforcement to deter non‑compliance — a heavy administrative and contractual lift.
Practically, PBMs will need to renegotiate contracts, plans will need new accounting and reconciliation systems, and auditors will need access to proprietary contract terms. The bill attempts to balance disclosure with confidentiality (audit‑only access, aggregated public data) but operational gaps will show up as plans and vendors translate legal requirements into technical specs and data feeds.
On preparedness the bill funds and creates structures (regional labs, wastewater grants, supply‑chain working groups) that expand capacity, but it also layers additional planning and reporting on already stretched state public‑health departments. Many public‑health grants carry maintenance‑of‑effort and reporting conditions; states without implementation funds will confront hard choices.
For FDA and NIH, the bill adds pediatric and rare‑disease study rules and mandates guidance and reviews; industry will want regulatory clarity quickly for clinical trial designs, and FDA will be under pressure to issue usable guidance on timelines that intersect with industry development cycles.
Unresolved questions include how to standardize the PBM reports across platforms; how enforcement authorities across ERISA, tax code and HHS will be coordinated in practice; and whether vaccine‑ and countermeasure‑related transitions between injury compensation programs (table inclusion vs. countermeasure declarations) will create unintended gaps in claimant rights. Also, the bill directs many timelines for guidance and rulemaking — those deliverables will determine whether implementation is feasible or disruptive.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.